Potential Therapeutic Targets for Combination Antibody Therapy Against <i>Staphylococcus aureus</i> Infections

• Main Authors: Sharon Ke (Author), Hyein Kil (Author), Conner Roggy (Author), Ty Shields (Author), Zachary Quinn (Author), Alyssa P. Quinn (Author), James M. Small (Author), Francina D. Towne (Author), Amanda E. Brooks (Author), Benjamin D. Brooks (Author)
• Format: Book
• Published: MDPI AG, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Despite the significant advances in antibiotic treatments and therapeutics, <i>Staphylococcus aureus</i> (<i>S. aureus</i>) remains a formidable pathogen, primarily due to its rapid acquisition of antibiotic resistance. Known for its array of virulence factors, including surface proteins that promote adhesion to host tissues, enzymes that break down host barriers, and toxins that contribute to immune evasion and tissue destruction, <i>S. aureus</i> poses a serious health threat. Both the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) classify <i>S. aureus</i> as an ESKAPE pathogen, recognizing it as a critical threat to global health. The increasing prevalence of drug-resistant <i>S. aureus</i> underscores the need for new therapeutic strategies. This review discusses a promising approach that combines monoclonal antibodies targeting multiple <i>S. aureus</i> epitopes, offering synergistic efficacy in treating infections. Such strategies aim to reduce the capacity of the pathogen to develop resistance, presenting a potent adjunct or alternative to conventional antibiotic treatments.

Item Description

10.3390/antibiotics13111046
2079-6382